SENTI BIOSCIENCES HOLDINGS I
SNTI · NASDAQ
更新於 2026-10-13 15:18:11
- 今日最高
- $0.32
- 今日最低
- $0.30
%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23150%3B%26%23135%3B%26%23230%3B%26%23161%3B%26%23163%3B%26%23230%3B%26%23154%3B%26%23151%3B%26%23232%3B%26%23167%3B%26%23146%3B%22%20d%3D%22M48.3363%2013.4132H60.2082L46.795%205.72205e-06V11.8719C46.795%2012.7231%2047.4851%2013.4132%2048.3363%2013.4132Z%22%20fill%3D%22var(--fill-0%2C%20%23474741)%22%2F%3E%0A%3Cpath%20id%3D%22%26%23230%3B%26%23148%3B%26%23190%3B%26%23229%3B%26%23164%3B%26%23167%3B%26%23233%3B%26%23149%3B%26%23156%3B%22%20fill-rule%3D%22evenodd%22%20clip-rule%3D%22evenodd%22%20d%3D%22M11.3812%2020.3725C16.7977%2014.9559%2025.5803%2014.9559%2030.9969%2020.3725C36.413%2025.789%2036.4131%2034.5707%2030.9969%2039.9872C26.0109%2044.973%2018.1729%2045.3699%2012.7335%2041.1769L2.54298%2051.3684L0%2048.8254L10.1915%2038.6329C5.99993%2033.1937%206.39609%2025.3579%2011.3812%2020.3725ZM28.4539%2022.9155C24.4418%2018.9033%2017.9363%2018.9033%2013.9241%2022.9155C9.91245%2026.9275%209.91241%2033.4322%2013.9241%2037.4442C17.9362%2041.4562%2024.4418%2041.4562%2028.4539%2037.4442C32.4656%2033.4322%2032.4656%2026.9275%2028.4539%2022.9155Z%22%20fill%3D%22var(--fill-0%2C%20%235D5D56)%22%2F%3E%0A%3C%2Fg%3E%0A%20%20%3C%2Fsvg%3E%0A%3C%2Fsvg%3E%0A)
K線圖趨勢，實際資料以交易頁為準
關鍵數據
- 昨天開盤價
- $0.31
- 昨天收盤價
- $0.31
- 成交量
- 142.79K
- 市值
- $9.92M
- 市盈率（P/E）
- --
- 每股收益（EPS）
- $-1.76
昨天價格區間
52週價格區間
公司概況
- 板塊
- HEALTHCARE
- 行業
- Biotechnology
- 子行業
- BIOTECHNOLOGY
- 總部
- 2 CORPORATE DRIVE, SOUTH SAN FRANCISCO, CA, UNITED STATES, 94080
- 國家
- US
- 上市日期
- 2021-05-26
- 財年截止
- December
- 流通股數
- 31.14M
- CIK
- 0001854270
- 官方網址
- www.sentibio.com
Senti Biosciences Inc (SNTI) is a leading biotechnology firm specializing in synthetic biology, leveraging its proprietary GeneCircuit platform to create programmable cell and gene therapies. Focused on advancing personalized medicine, Senti targets critical challenges in oncology and genetic disorders, bolstered by a strong development pipeline and strategic collaborations. The company is poised for growth as it aims to revolutionize engineered cell therapy and address substantial unmet medical needs within the biopharmaceutical landscape, making it a compelling prospect for institutional investors.
財務指標
營業收入
2026-06-30
$17K
2026-03-31
$16K
2025-12-31
$22K
2025-09-30
$0
營業支出
2026-06-30
$13.83M
2026-03-31
$11.51M
2025-12-31
$12.71M
2025-09-30
$16.94M
淨利潤
2026-06-30
-$12.75M
2026-03-31
-$4.22M
2025-12-31
-$14.46M
2025-09-30
-$18.12M
淨利潤率
2026-06-30
-75K%
2026-03-31
-26.38K%
2025-12-31
-65.75K%
2025-09-30
--
每股收益
2026-06-30
$-0.41
2026-03-31
$-0.14
2025-12-31
$-0.53
2025-09-30
$-0.69
息稅折舊攤銷前利潤
2026-06-30
-$13.82M
2026-03-31
-$3.53M
2025-12-31
-$13.57M
2025-09-30
-$16.04M
有效稅率
2026-06-30
--
2026-03-31
--
2025-12-31
--
2025-09-30
--
| 項目 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| 營業收入 | $17K | $16K | $22K | $0 |
| 營業支出 | $13.83M | $11.51M | $12.71M | $16.94M |
| 淨利潤 | -$12.75M | -$4.22M | -$14.46M | -$18.12M |
| 淨利潤率 | -75K% | -26.38K% | -65.75K% | -- |
| 每股收益 | $-0.41 | $-0.14 | $-0.53 | $-0.69 |
| 息稅折舊攤銷前利潤 | -$13.82M | -$3.53M | -$13.57M | -$16.04M |
| 有效稅率 | -- | -- | -- | -- |
常見問題
風險提示
股價可能大幅波動，短時間內可能出現顯著漲跌。 數位資產與衍生性商品交易可能涉及槓桿、流動性等額外風險。 本頁內容僅供參考，不構成任何投資建議。 產品可用性與訪問可能因地區及適用法規而異。